FuzzyBot: Importing a new version from external source

2024-03-12T08:34:24Z

Importing a new version from external source

New page

==Examples==
Drugs belonging to this class are:
* [[Sitagliptin]] (FDA approved 2006, marketed by [[Merck & Co.]] as [[Januvia]])
* [[Vildagliptin]] (EU approved 2007, marketed in the EU by [[Novartis]] as Galvus)
* [[Saxagliptin]] (FDA approved in 2009, marketed as [[Onglyza]])
* [[Linagliptin]] (FDA approved in 2011, marketed as Tradjenta by [[Eli Lilly and Company]] and [[Boehringer Ingelheim]])
* [[Gemigliptin]] (approved in Korea in 2012, marketed by [[LG Chem|LG Life Sciences]]) Marketed as Zemiglo
* [[Anagliptin]] (approved in Japan as Suiny in 2012, marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and [[Kowa (company)|Kowa Company, Ltd.]])
* [[Teneligliptin]] (approved in Japan as Tenelia in 2012)
* [[Alogliptin]] (FDA approved 2013 as Nesina/ Vipidia, marketed by [[Takeda Pharmaceutical Company]])
* [[Trelagliptin]] (approved for use in Japan as Zafatek/ Wedica in 2015)
* [[Omarigliptin]] (MK-3102) (approved as Marizev in Japan in 2015, developed by [[Merck & Co.]]; research showed that omarigliptin can be used as once-weekly treatment and generally well tolerated throughout the base and extension studies)
* [[Evogliptin]] (approved as Suganon/ Evodine for use in South Korea)
* [[Gosogliptin]] (approved as Saterex for use in Russia)
* [[Dutogliptin]] (PHX- 1149 free base, being developed by [[Phenomix Corporation]]), Phase III
* [[Retagliptin]] (SP-2086), approved in China.
*[[Denagliptin]]
* [[Cofrogliptin]] (HSK- 7653, compound 2)
* [[Fotagliptin]]
* [[Prusogliptin]]

Translations:Dipeptidyl peptidase-4 inhibitor/6/en - Revision history

FuzzyBot: Importing a new version from external source